Proteoglycan expression in bleomycin lung fibroblasts: role of transforming growth factor-beta 1 and interferon-gamma

Narayanan Venkatesan1, Peter J. Roughley2, and Mara S. Ludwig1

1 Meakins-Christie Laboratories, Royal Victoria Hospital; and 2 Genetics Unit, Shriners Hospital for Crippled Children, McGill University, Montreal, Quebec, Canada H2X 2P2


    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Bleomycin (BM)-induced pulmonary fibrosis involves excess production of proteoglycans (PGs). Because transforming growth factor-beta 1 (TGF-beta 1) promotes fibrosis, and interferon-gamma (IFN-gamma ) inhibits it, we hypothesized that TGF-beta 1 treatment would upregulate PG production in fibrotic lung fibroblasts, and IFN-gamma would abrogate this effect. Primary lung fibroblast cultures were established from rats 14 days after intratracheal instillation of saline (control) or BM (1.5 units). PGs were extracted and subjected to Western blot analysis. Bleomycin-exposed lung fibroblasts (BLF) exhibited increased production of versican (VS), heparan sulfate proteoglycan (HSPG), and biglycan (BG) compared with normal lung fibroblasts (NLF). Compared with NLF, BLF released significantly increased amounts of TGF-beta 1. TGF-beta 1 (5 ng/ml for 48 h) upregulated PG expression in both BLF and NLF. Incubation of BLF with anti-TGF-beta antibody (1, 5, and 10 µg/ml) inhibited PG expression in a dose-dependent manner. Treatment of BLF with IFN-gamma (500 U · ml-1 × 48 h) reduced VS, HSPG, and BG expression. Furthermore, IFN-gamma inhibited TGF-beta 1-induced increases in PG expression by these fibroblasts. Activation of fibroblasts by TGF-beta 1 promotes abnormal deposition of PGs in fibrotic lungs; downregulation of TGF-beta 1 by IFN-gamma may have potential therapeutic benefits in this disease.

lung fibrosis; versican; heparan sulfate proteoglycan; biglycan


    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

THE LUNG EXTRACELLULAR MATRIX (ECM) consists of collagen and elastic fibers interspersed with structural glycoproteins and proteoglycans (PGs; see Ref. 8). PGs, a heterogeneous group of macromolecules, consist of a core protein to which glycosaminoglycan chains are covalently attached. PGs influence lung tissue mechanical properties and, through their interactions with various macromolecules, contribute to a variety of biological functions such as water balance, cell adhesion, cell migration, and growth factor binding within the ECM (1, 20, 33). Versican (VS), the large aggregating chondroitin sulfate containing PG, forms macromolecular aggregates with hyaluronic acid in the lung interstitial matrix. In addition, perlecan, a heparan sulfate proteoglycan (HSPG), and several small leucine-rich repeat PGs, i.e., biglycan (BG), decorin, fibromodulin, and lumican, have been identified in the lung tissue (11, 33, 43). Changes in ECM synthesis and degradation play a part not only in physiological processes such as development, growth, and aging but also in wound healing, inflammation, and fibrosis (33, 37).

Bleomycin (BM)-induced pulmonary fibrosis, a well-established animal model for the study of human pulmonary fibrosis, is an inflammatory interstitial lung disease characterized by excessive accumulation of fibroblasts and ECM molecules, including PGs, in the intraluminal and interstitial compartments of the lung (8, 40, 43). Evidence from human studies and animal models indicates that transforming growth factor (TGF)-beta 1 plays a pivotal role in mediating pathophysiological changes in fibrotic diseases (37). TGF-beta 1 stimulates fibroblasts to synthesize large amounts of ECM proteins. TGF-beta 1 levels are upregulated in patients with cryptogenic fibrosing alveolitis and also in BM-induced lung fibrosis (BLF) in rats (23).

Fibroblasts participate in inflammatory responses and wound repair through their ability to release cytokines, secrete ECM proteins, and through cell-cell interactions with other inflammatory cells such as macrophages. At sites of injury and wound repair, fibroblasts have been shown to migrate from different anatomic sites and transform into a less proliferative but more contractile and collagen synthetic phenotype (14, 32). It has been reported that lung fibroblasts cultured from BM-induced fibrotic rat lungs produced more collagen than normal lung fibroblasts (NLF) in culture (30). Furthermore, Raghu et al. (31) demonstrated that TGF-beta 1 stimulated collagen production and collagen mRNA levels in fibroblasts derived from normal and fibrotic human lungs.

Although the effect of TGF-beta 1 on collagen expression in NLF and BLF has been relatively well defined, the pattern of synthesis of PGs by NLF and BLF and the effects of TGF-beta 1 on PG production have not been investigated. This is of particular interest because PGs are one of the first ECM components to be upregulated in the fibrotic process and may be critical in establishing the provisional matrix necessary for subsequent cell migration and proliferation (33). Moreover, an increase in TGF-beta 1, both at the messenger and protein levels, occurs well before any detectable increase in the expression of collagens in BM-induced pulmonary fibrosis (19). We have recently reported marked increases in both the large and small PGs in BM-induced pulmonary fibrosis in intact rats (12, 40). Based on these observations, we hypothesized that the upregulation of PGs in fibrotic lungs may be because of an increase in the biosynthetic activity of resident fibroblasts. Moreover, we postulated a role for TGF-beta 1 in this process, as has been shown in other organ systems (4, 22).

The observation by Giri and colleagues (16, 41) that anti-TGF-beta antibodies and TGF-beta -soluble receptors were effective in inhibiting BLF highlights TGF-beta 1 as a potential candidate for therapeutic intervention. Subsequent studies found decorin, a small PG and a natural inhibitor of TGF-beta 1, to ameliorate various fibrotic disorders, including BLF (15). Interferon-gamma (IFN-gamma ), a major effector cytokine produced by activated T lymphocytes and natural killer cells, has immunomodulatory, antiviral, and antiproliferative properties (3). It modulates the metabolism of connective tissue cells, inhibiting fibroblast proliferation and the production of collagenous and noncollagenous ECM proteins (9). Gurujeyalakshmi and Giri (17) reported that IFN-gamma downregulates TGF-beta 1 and collagen gene expression in the BM model of lung fibrosis. IFN-gamma has also been shown to inhibit the growth of fibroblast cultures and collagen synthesis derived from normal and fibrotic human lungs (27). However, the role of IFN-gamma in providing protection against increases in PG production by BM lung fibroblasts remains poorly defined.

Therefore, we compared PG production by NLF and BLF. We also investigated the modulating effect of TGF-beta 1 on PG production and determined whether endogenous TGF-beta -induced increases in PG production would be abrogated by the addition of neutralizing anti-TGF-beta antibodies. Finally, the anti-fibrotic effect of IFN-gamma on TGF-beta 1-induced increases in PG expression was studied.


    MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Chemicals. Reagents were obtained from the following sources: BM (Blenoxane) from Bristol-Myers Squibb (Princeton, NJ); agarose from Park Scientific (Northampton, UK); acrylamide, 6-aminohexanoic acid, benzamidine hydrochloride, chondroitinase avidin-biotin complex (ABC), EDTA, N-ethylmaleimide (NEM), guanidine hydrochloride (GuHCl), N,N'-methylene-bisacrylamide, N,N,N',N'-tetra methyethylenediamine, L-glutamine, phenylmethylsulfonyl fluoride (PMSF), sodium acetate, Trizma base, Tween 20, and monoclonal antibodies anti-vimentin and anti-alpha smooth muscle actin (alpha -SMA) from Sigma (Oakville, ON, Canada); monoclonal antibodies 12C5 and C17 from Developmental Studies Hybridoma Bank (Iowa City, IA); hyperfilm, Hybond enhanced chemiluminescence (ECL) nitrocellulose membrane, molecular weight standards, ECL Western blotting detection reagents, and streptavidin-biotinylated horseradish peroxidase (HRP) complex from Amersham Pharmacia Biotech (QC, Canada); collagenase type I, DNase, DMEM, FBS, fungizone, IFN-gamma , penicillin-streptomycin, PBS, recombinant human TGF-beta 1, and trypsin from GIBCO (Burlington, ON, Canada); pan-specific TGF-beta antibody and TGF-beta 1 enzyme-linked immunosorbent assay kit from R&D Systems.

Experimental design. Pulmonary fibrosis was induced in male Sprague-Dawley rats (weight: 275-350 g) by a single intratracheal instillation of 1.5 units BM in 0.3 ml saline. Control rats received an equal volume of saline. Control and BM rats were killed at 14 days by exanguination under phenobarbitol sodium anesthesia according to standard ethical procedures. Using sterile techniques, the lungs were perfused until they were pale with sterile PBS via the right ventricle. The lungs were removed and trimmed of extraneous tissues and bronchial and vascular structures.

Primary rat lung fibroblast culture. Cultures of rat lung fibroblasts were established by enzymatic dissociation of finely minced lung tissues according to the standard protocol of Phan et al. (30) with slight modifications. Tissue fragments (after mincing into 2- to 4-mm pieces) were digested in DMEM containing trypsin (2.5 mg/ml), collagenase (1 mg/ml), and DNase I (2 mg/ml) and incubated with gentle stirring at 37°C in 5% CO2-95% O2 in humidified air for 30 min. Digestion was carried out for three cycles of 30 min each, with removal of medium and free cells after each cycle and the addition of fresh medium for each successive cycle. Medium removed at the completion of each cycle was mixed with an equal volume of DMEM. Pooled liberated cells, collected and separated from undigested tissue and debris, were filtered through sterile gauze and centrifuged to pellet cells. The pelleted cells were washed two times with PBS and DMEM containing 10% FBS and finally suspended in this media. The cells were then incubated in a 5% CO2 incubator at 37°C. After 24-48 h, unattached cells were removed by washing, and fresh medium was added. After another 48 h, cells were confluent and harvested by trypsinization with 0.25% trypsin-EDTA for 3-5 min at 37°C and then counted and split 1:3. Fibroblasts were maintained in DMEM + 10% FBS containing 2 mM L-glutamine, 0.37 g of sodium bicarbonate/100 ml, 200 units penicillin/ml, 200 µg/ml streptomycin sulfate, and 2.5 µg/ml fungizone. Cells were passaged every 3-5 days, and by the fourth passage they were homogeneous monolayers (morphologically consistent with fibroblast-like cells, phase-contrast light microscopy). Experiments were carried out with fibroblasts between the fourth and sixth passages.

Phenotypic characterization of lung fibroblasts. Immunofluorescent staining was used to characterize the phenotype of isolated lung fibroblasts. Lung fibroblasts were grown to subconfluence on glass coverslips and fixed with ice-cold acetone for 20 min at -20°C. The cells were then treated with 70% ethanol for 5 min at -20°C. The cells were washed in sterile PBS and incubated with mouse monoclonal antibodies for vimentin (a fibroblast marker) and alpha -SMA for 1 h at room temperature. The cells were washed again in PBS and reincubated with fluorescent goat anti-mouse IgG (Molecular Probes, Eugene, OR) for 45 min at room temperature. After being washed in PBS, the coverslips were sealed with crystal mount, and the fluorescence pattern was examined by confocal microscopy. Negative controls were processed similarly, except incubation with the primary antibody was omitted.

Determination of cell proliferation and cell viability. Fibroblast proliferation was assayed by direct cell counting. Fibroblasts were seeded at a density of 1 × 105 cells in 25-cm2 culture flasks in DMEM + 0.1% FBS, and the rates of growth were measured with or without TGF-beta 1 at 24, 48, and 72 h. Cells were trypsinized and placed in a hemocytometer for actual cell counting using a microscope. Experiments were performed in triplicate with cells obtained from saline and BM-exposed rat lungs. Cell viability was determined by the trypan blue exclusion test.

Characterization of PGs synthesized by fibroblasts in culture. Fibroblasts were grown to confluence and then serum deprived (0.1% FBS) for 24 h before stimulation with TGF-beta 1 (5 ng/ml), anti-TGF-beta antibody (1, 5, or 10 µg/ml), IFN-gamma (5, 50, or 500 U/ml), or TGF-beta 1 + IFN-gamma (5, 50, or 500 U/ml) for 48 h. The amount of TGF-beta 1 used in the present study was based on a previous study on collagen production using fibroblasts derived from fibrotic human lung (31). At the end of the experimental period, PGs were fractionated into cell layer and medium compartments. The cell layer was rinsed three times with PBS and extracted with ice-cold 4 M GuHCl-50 mM sodium acetate (pH 5.8)-1% Triton X-100 containing the following proteinase inhibitor cocktail: 100 mM 6-aminohexanoic acid-10 mM EDTA-5 mM benzamidine hydrochloride-10 mM NEM-0.1 mM PMSF at 4°C overnight. The PG extracts were then centrifuged at 15,000 revolutions/min for 30 min; the supernatants were dialyzed exhaustively against 50 mM Tris · HCl (pH 8.0) containing proteinase inhibitors and distilled water and concentrated; then protein content was estimated. Cell culture media were dialyzed as described above, and then protein content was measured (Bio-Rad protein assay).

Composite agarose-PAGE and Western blotting of VS and HSPG. Electrophoretic separation of large PGs was performed in a composite gel (0.6% agarose-1.2% polyacrylamide), as described previously (40). Samples were run in the gel at 60 volts and then separated at 160 volts until the bromphenol blue marker migrated to 3 cm. Separated PGs were electrophoretically transferred and probed with antibodies to VS or large basement membrane HSPGs. After electrophoresis, separated PGs were transferred to nitrocellulose membranes using a Bio-Rad (Mississauga, ON, Canada) blotter apparatus (20 volts overnight at 4°C). After blocking, membranes were probed with monoclonal antibodies 12C5 (1:2,000) or C17 (1:1,000) to detect VS or large basement membrane HSPGs, respectively, in Tris-buffered saline with Tween [TBST; 10 mM Tris · HCl (pH 8.0), 150 mM NaCl, and 0.05% Tween 20] for 1 h at room temperature. After washing with TBST, membranes were incubated with a biotinylated rabbit antimouse secondary antibody (1:2,500) for 1 h at room temperature, washed again with TBST, and then incubated in streptavidin-biotinylated HRP complex (1:3,000) for 45 min at room temperature. After washing of membranes, antibody binding was visualized through ECL detection.

SDS-PAGE and Western blotting of BG. Specific polyclonal antipeptide IgG that has been previously shown to interact with BG in human cartilage extracts (34) was used to identify the expression of BG protein expressed by lung fibroblasts. PG extracts were digested with chondroitinase ABC (0.1 U/ml at 37°C for 4 h), run in a 10% SDS-PAGE gel, and then analyzed by immunoblotting. After electrophoresis, the separated proteins were electrophoretically transferred to nitrocellulose membranes and blocked for 1 h at 20°C. After blocking, membranes were washed with TBST and then incubated with primary antibodies for 1 h at room temperature to detect BG (1:500 dilution) core protein. After being washed with TBST, membranes were incubated with a 1:1,000 dilution of biotin-labeled swine anti-rabbit secondary antibody for 1 h at 20°C. After further washing with TBST, membranes were incubated in streptavidin-biotinylated HRP complex (1:5,000) for 45 min at room temperature, washed one time again, and then visualized by ECL detection.

Quantification of immunoblots. Densitometric analysis of both the large and small PGs was accomplished with image analyzer software (Fluorchem; Alpha Innotech, San Leandro, CA), which measures the sum of all the pixel values after background correction. The mean values of three experiments are presented.

Measurement of TGF-beta 1 in cell-conditioned medium. The concentration of TGF-beta 1 released by NLF and BLF was determined using a human TGF-beta 1 enzyme-linked immunosorbent assay kit (R&D Systems) that detects rat TGF-beta 1 protein. Briefly, NLF and BLF were plated and grown to confluency in complete medium containing 10% FBS. Next, these cells were washed in PBS and incubated in a serum-free medium containing 0.2 mg/ml BSA. The medium was changed every 4 h for a period of 24 h. After 24 h, the conditioned media were separated from cells and centrifuged. The cell-free conditioned media were assayed for TGF-beta 1 after acidification and neutralization according to the manufacturer's protocol. All assays were done in duplicate wells. The assay detects only the active form of TGF-beta 1, and the results, normalized to an equal number of cells, were expressed as nanograms per milliliter per 106 cells.

Statistical analysis. All data are presented as means ± SD of three observations. Student's unpaired t-test was used to analyze the statistical significance of the differences between the results of NLF and BLF and that of cells treated with or without TGF-beta 1. One-way ANOVA with post hoc Bonferroni correction was used to determine the significance of dose-response studies with neutralizing anti-TGF-beta antibody and IFN-gamma . Statistical analyses were performed using GraphPad Prism software (version 3.0).


    RESULTS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Characterization of lung fibroblasts. Immunofluorescent studies on cultured cells revealed that both NLF (Fig. 1A) and BLF (Fig. 1B) were strongly positive for vimentin (a fibroblast marker). There was no systematic difference between NLF and BLF in the staining pattern of vimentin. We also stained the isolated fibroblasts with alpha -SMA (a smooth muscle marker). The results demonstrated that NLF (Fig. 1C) expressed a weak signal for alpha -SMA, whereas BLF (Fig. 1D) contained more cells positive for alpha -SMA.


View larger version (103K):
[in this window]
[in a new window]
 
Fig. 1.   Immunofluorescence staining of vimentin and alpha -smooth muscle actin in lung fibroblasts. Isolated lung fibroblasts were cultured on glass coverslips and fixed with acetone before staining for vimentin and alpha -smooth muscle actin, as described under MATERIALS AND METHODS. Both normal lung fibroblasts (NLF; A) and bleomycin-exposed lung fibroblasts (BLF; B) demonstrated positive staining for vimentin. alpha -Smooth muscle actin expression was increased in BLF (D) compared with NLF (C).

Growth rate and cell viability. In a previous study, we observed a maximal increase in lung PGs at 14 days post-BM treatment (40): lung fibroblasts were isolated at this time point in the current study. The growth rate of BLF did not differ significantly from NLF (data not shown). Because TGF-beta 1 is a potent regulator of growth, cell proliferation was also measured in the presence of exogenously added TGF-beta 1. The results revealed no change in proliferation rate, indicating TGF-beta 1 did not affect growth rates in either NLF or BLF. We were also interested in determining whether TGF-beta 1 or anti-TGF-beta antibody had any cytotoxic effects on these fibroblasts. To this end, we used the trypan blue exclusion method to assess cell viability. Our results indicated that neither TGF-beta 1 nor anti-TGF-beta antibody caused detachment of cells from the culture flask. More than 95% of cells were attached to the culture flask and excluded trypan blue stain.

BLF express increased amounts of PGs at the protein levels in vitro. Similar results were obtained for both the cell layer and medium compartments with regard to PG expression; therefore, in the present study, we present the data obtained from the cell layer.

Our data indicate that NLF and BLF differ in their ability to produce PGs in vitro. BLF demonstrated a 7.3-fold increase in the in vitro expression of VS (Fig. 2B) in the cell layer compared with NLF (Fig. 2A). Two immunoreactive bands were detected on composite gels for VS, suggesting that the protein has two isoforms, perhaps because of alternative splicing of the VS gene. We observed a 3.6-fold increase of HSPG in the cell layer of BLF (Fig. 3B) compared with NLF (Fig. 3A). Finally, BLF (Fig. 4B) produced larger amounts (3.5-fold increase) of cell-associated BG compared with NLF (Fig. 4A).


View larger version (16K):
[in this window]
[in a new window]
 
Fig. 2.   Immunoblot analysis and quantification of versican expression in the cell layer of NLF (A) and BLF (B). Fibroblasts derived from saline or bleomycin-exposed lungs were exposed to transforming growth factor (TGF)-beta 1 (5 ng/ml), neutralizing anti-TGF-beta antibody (1, 5, or 10 µg/ml), interferon (IFN)-gamma (500 U), or TGF-beta 1 + IFN-gamma for 48 h and then extracted for proteoglycans. Extracted proteoglycans were run on composite gels and probed with 12C5 antibody to detect the versican epitope as described under MATERIALS AND METHODS. Data are means ± SD of 3 independent observations.



View larger version (15K):
[in this window]
[in a new window]
 
Fig. 3.   Immunoblot analysis and quantification of heparan sulfate proteoglycan (HSPG) expression in the cell layer of NLF (A) and BLF (B). Fibroblasts isolated from saline- or bleomycin-treated rats were treated with or without TGF-beta 1 (5 ng/ml), neutralizing anti-TGF-beta antibody (1, 5, or 10 µg/ml), IFN-gamma (500 U), or TGF-beta 1 + IFN-gamma for 48 h. Proteoglycans isolated from the cell layer were run on a agarose-polyacrylamide gel and then probed with C17 antibody to detect the HSPG epitope, as described under MATERIALS AND METHODS. Data are means ± SD of 3 separate experiments.



View larger version (16K):
[in this window]
[in a new window]
 
Fig. 4.   Immunoblot analysis and quantification of cell-associated biglycan in NLF (A) and BLF (B) treated with or without TGF-beta 1 (5 ng/ml), neutralizing anti-TGF-beta antibody (1, 5, or 10 µg/ml), IFN-gamma (500 units), or TGF-beta 1 + IFN-gamma for 48 h. Cell layer proteoglycans were separated by SDS-PAGE on 10% gels and probed with a specific polyclonal antipeptide IgG for biglycan core protein, as described under MATERIALS AND METHODS. Values are means ± SD of 3 separate experiments.

BLF secrete higher amounts of TGF-beta 1 protein. To investigate the hypothesis that enhanced expression of PGs in BLF may be the result of increased expression of TGF-beta 1, we measured the levels of TGF-beta 1 released in serum-free cell-conditioned media of NLF and BLF. Our results demonstrated that there was a significant increase (3.4-fold increase) in TGF-beta 1 protein secreted by BLF (Fig. 5) compared with NLF.


View larger version (5K):
[in this window]
[in a new window]
 
Fig. 5.   Measurement of TGF-beta 1 release in cell-conditioned media of NLF and BLF. After confluency, NLF and BLF were cultured in serum-free media for a period of 24 h, and the conditioned media was analyzed for bioactive TGF-beta 1 protein, as described under MATERIALS AND METHODS. Compared with NLF, BLF secreted significantly increased amounts of TGF-beta 1. Values are means ± SD of 3 separate experiments.

TGF-beta 1 upregulates PG expression in NLF and BLF in vitro. After exposure to TGF-beta 1 (5 ng/ml), there was a twofold increase in VS in the cell layer of BLF (Fig. 1B). BLF exposed to TGF-beta 1 exhibited a 3.8-fold increase of HSPG in the cell layer (Fig. 3B) and a 3.2-fold increase in the cell-associated BG (Fig. 4B).

Similarly, NLF increased the expression of PGs at the protein level in response to TGF-beta 1 stimulation. A 4.4-fold increase in the expression of VS in the cell layer was observed for NLF treated with TGF-beta 1 (Fig. 2A). NLF treated with TGF-beta 1 demonstrated a 5.5-fold increase for cell-associated HSPG (Fig. 3A). Similarly, a 3.6-fold increase in the expression of BG in the cell layer was noted for NLF treated with TGF-beta (Fig. 4A).

Neutralizing antibody to TGF-beta decreases PG expression in fibroblasts. There was a dose-dependent decrease in PG expression in response to neutralizing antibody. Although the lowest concentration (1 µg/ml) of anti-TGF-beta antibody had no inhibitory effect on PG expression, incubation with 5 and 10 µg/ml significantly modulated PG production. As shown in Fig. 1B, anti-TGF-beta antibody at 5 and 10 µg/ml inhibited 48.9 and 86.7% of VS expression, respectively, in the cell layer obtained for BLF. Anti-TGF-beta antibody treatment resulted in a 57.4 and 80.8% inhibition of HSPG expression in the cell layer (Fig. 3B) at 5 and 10 µg/ml, respectively, in BLF. Anti-TGF-beta antibody treatment led to a 40.9 and 62.6% inhibition of BG in the cell layer at 5 and 10 µg/ml (Fig. 4B), respectively, for BLF.

We also investigated whether NLF responds to the antifibrotic effects of anti-TGF-beta antibody. Neutralizing antibody significantly reduced the basal levels of PG expression in NLF. Quantification of Western blots of cell-associated PGs showed that anti-TGF-beta antibody at 10 µg/ml inhibited 53.6% of VS expression in NLF (Fig. 2A). Similarly, NLF treated with 10 µg/ml demonstrated a significant decrease in HSPG production (54.5% inhibition for cell-layer PGs; Fig. 3A). Treatment of NLF with 10 µg/ml anti-TGF-beta antibody resulted in a 54% inhibition in the expression of cell-associated BG (Fig. 4A). These results clearly indicate that inhibition of endogenous TGF-beta activity results in downregulation of PGs in both NLF and BLF.

IFN-gamma reduces PG expression in fibroblasts. To determine whether IFN-gamma can suppress PG protein expression in BLF, we used three different concentrations of IFN-gamma (5, 50, or 500 U/ml). We found that the two lower concentrations (5 and 50 U/ml) had no significant effect in reducing PG production, whereas IFN-gamma at 500 U/ml markedly decreased PG expression. A 64, 63, and 62% inhibition of VS (Fig. 2B), HSPG (Fig. 3B), and BG (Fig. 4B) expression, respectively, was observed in the cell layer of BLF treated with 500 U/ml IFN-gamma . We were also interested in determining whether IFN-gamma treatment would block the TGF-beta 1-induced increases in PG expression by fibroblasts. Whereas the two lower concentrations (5 or 50 U/ml) of IFN-gamma resulted in no inhibitory effect on PG expression, IFN-gamma treatment at a dose of 500 U/ml resulted in a 74, 61, and 76% inhibition of VS (Fig. 2A), HSPG (Fig. 3A), and BG (Fig. 4A), respectively, in NLF treated with TGF-beta 1. Similarly, IFN-gamma treatment resulted in a 75, 78, and 67% inhibition of VS (Fig. 2B), HSPG (Fig. 3B), and BG (Fig. 4B) expression, respectively, in BLF treated with TGF-beta 1.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

The most significant findings of the present study are 1) BLF produced larger amounts of all classes of PGs than NLF, 2) BLF secreted increased amounts of TGF-beta 1 protein than NLF, 3) exposure of fibroblasts to exogenous TGF-beta 1 stimulated these cells to produce more PGs than untreated cells, 4) anti-TGF-beta antibody inhibited the levels of PGs expressed by these fibroblasts in a dose-dependent fashion, and 5) IFN-gamma attenuated the TGF-beta 1-induced increases in PG expression. In the present study, we have analyzed PG expression at the protein level. PG expression at the mRNA level would have provided additional information; however, the presence of mRNA does not necessarily predict protein production. A previous study on cytokine regulation of PG expression in lung fibroblasts has reported that changes in mRNA levels for the various PGs were not consistent with changes in protein production (38).

We questioned whether BM induced phenotypic changes in lung fibroblasts. Previous studies have demonstrated the emergence of myofibroblasts as the predominant cell type involved in the increased deposition of ECM proteins and enhanced contractility of lung tissue in this disease process (13, 24, 26, 44). Our findings are in agreement with these studies, in so far as the BM fibroblasts showed positive staining for both vimentin and alpha -SMA and hence a phenotype more consistent with that of the myofibroblast. Whether this specific cell type produces relatively increased amounts of PGs upon cytokine stimulation warrants investigation.

The marked upregulation of PGs by BLF, and the significant response to TGF-beta 1, are relevant to events in the development of pulmonary fibrosis. Increased VS expression may be of importance in providing the provisional matrix for cell migration and cell proliferation (2, 33). This provisional matrix may be required for subsequent collagen deposition (2). In this regard, VS is one of the early response ECM components to be upregulated during the development of BM-induced pulmonary fibrosis (2). Given the observation that HSPG binds to growth factors and regulates cell growth and cell-matrix interactions (21), its upregulation by BLF could influence many cellular functions pertinent to fibrosis. Because the core protein of BG has been shown to bind to collagens and fibronectin, it may modulate cell adhesion, cell migration, and collagen fiber assembly during fibrogenic processes (35). Furthermore, in a recent study from this laboratory, BG expression was correlated with biomechanical changes in lung tissue behavior (12). Hence these molecules may also be important in determining the mechanical changes observed in this disease process.

During the development of pulmonary fibrosis, fibroblasts are exposed to a number of inflammatory mediators, including eicosanoids, immune complexes, serum components, inflammatory growth and differentiation factors, and cytokines, many of which have the potential to influence fibroblast function (8). In addition, resident fibroblasts participate in the inflammatory response with other inflammatory cells such as macrophages, resulting in fibroblast chemotaxis to sites of injury and excessive ECM synthesis and deposition (14). As a result, fibroblasts attain a different metabolic phenotype with increased biosynthetic activity, as evidenced by increased ECM gene expression (32).

In our study, PG production and secretion were significantly increased in BLF compared with NLF. Our results are consistent with the studies of Phan et al. (30), who reported that the BLF secreted increased amounts of collagen. BM has been reported to increase the synthesis of acidic glycosaminoglycans in cultured fibroblasts derived from carrageenin granuloma (29). Our data are also in agreement with findings of increased fibroblast PG production in other types of fibrotic disorders; human granulation tissue fibroblasts have been shown to produce increased amounts of PGs compared with human gingival fibroblasts (18).

Enhanced ECM synthesis and deposition could be attributed to an increase in fibroblast proliferation and/or synthetic capacity. However, there was no significant difference in growth rates, as measured by in vitro cell proliferation, between NLF and BLF. Similar results were reported by Phan et al. (30), who also showed no change in growth rates of NLF and BLF. Our results are also supported by the studies of Wegrowski et al. (42), who reported that fibroblasts derived from patients with primary hypertrophic osteopathy synthesized more PG with no change in cell proliferation. Thus the observed increases in PG production by BLF can be explained by either increased synthesis or decreased degradation. Our findings indicate an enhancement in PG biosynthetic activity by fibroblasts isolated from BM-exposed rat lungs compared with saline-exposed rat lungs. Fibroblasts may be "primed" by BM to increase PG production. This corroborates our previous in vivo findings of marked upregulation of these PGs in the lung tissue of BM-induced fibrosis in rats (12, 40). Enhanced secretion of PGs by fibroblasts may represent a mechanism to explain increased ECM deposition in this model.

TGF-beta 1 is believed to be a critical mediator involved in the fibrotic response through its ability to regulate ECM production (37). Normally, TGF-beta 1 is expressed in bronchiolar epithelial cells and interstitial fibroblasts. However, after tissue injury and inflammation, TGF-beta 1 is highly expressed in macrophages and mesenchymal endothelial and mesothelial cells of the lung (23). TGF-beta 1 is increased in biopsies from fibrotic lungs (23). Elevations in TGF-beta 1 mRNA and protein content precede the increased expression of collagens in BM-induced pulmonary fibrosis (19). BM has also been shown to modulate the expression of TGF-beta 1 in rat lung fibroblasts (6). These observations indicate that TGF-beta 1 contributes to the general lung fibrotic process. We questioned whether this cytokine would affect production of PGs by fibroblasts in the BM model. Indeed, in the current study, TGF-beta 1 increased the expression of PGs in both NLF and BLF. These observations are consistent with those demonstrated in previous in vitro studies using other tissue-specific fibroblasts. Dermal fibroblasts exposed to TGF-beta 1 increased their PG levels as follows: expression of VS, HSPG, and BG was upregulated (22). In general, the response to TGF-beta 1 stimulation by both NLF and BLF was similar. Interestingly, it was reported previously that fibrotic human lung fibroblasts and NLF exhibited a similar level of increase in collagen production in response to TGF-beta 1 treatment (31).

TGF-beta 1-induced PG production was not coupled to enhanced cell proliferation. The biological activity of TGF-beta 1 depends on cell type and culture conditions. Hence, in our experimental conditions, the proliferative effect of TGF-beta 1 may not have been evident. Our findings are in accordance with the studies of Schonherr et al. (36), who reported that TGF-beta 1 increased the synthesis of a large VS-like chondroitin sulfate PG by arterial smooth muscle cells without changing the smooth muscle growth rate. The present results suggest that the stimulation of PG production by TGF-beta 1 can occur independently of effects on cell proliferation.

The marked upregulation of PGs by BLF may be because of an increase in TGF-beta 1 expression by these cells in response to BM-induced lung injury. Accordingly, we compared the amount of TGF-beta 1 protein released by NLF and BLF. The results indicated that BLF secreted higher amounts of TGF-beta 1 protein than that of NLF, supporting our hypothesis that increased expression of PGs in BLF is the result of an increase in the expression of TGF-beta 1. Increased expression of TGF-beta 1 mRNA was observed in BM-induced pulmonary fibrosis in rats (43). Fibroblasts isolated from fibrotic human gingiva have been demonstrated to produce more TGF-beta 1 in vitro than normal fibroblasts, which in turn can stimulate PG production (39). We investigated the putative autocrine role of TGF-beta 1 in the overproduction of PGs in this model using neutralizing antibody to TGF-beta isoforms. The present findings revealed that the elevated production of PGs by BLF was significantly inhibited by anti-TGF-beta antibody in a dose-dependent manner. At the highest dose of anti-TGF-beta antibody, PG production by BLF was similar to the basal levels produced by NLF, that is, the enhanced PG synthesis was totally abrogated. Inhibition by neutralizing antibody to TGF-beta of PG production to near normal levels has also been demonstrated in rat fibrotic glomeruli (5). In addition, antibody to TGF-beta reduced the levels of fibronectin, laminin, and chondroitin sulfate PG in injured rat brain (25). The results of these studies suggest that increased production of TGF-beta plays a key role in the pathogenesis of fibrogenic diseases, including BLF. Furthermore, the significant reduction in PG production by NLF with anti-TGF-beta antibody treatment suggests that the constitutive production of PGs in these fibroblasts is also under autocrine control by TGF-beta .

IFN-gamma , a lymphokine produced by activated T lymphocytes, macrophages, and natural killer cells, has been shown to modulate the metabolism of connective tissue cells. Numerous studies have demonstrated that IFN-gamma has a regulatory role on collagen accumulation by inhibiting the synthesis of types I and III collagen and abrogating the stimulatory effect of TGF-beta 1 (17). IFN-gamma has been shown to inhibit the growth of fibroblasts and collagen synthesis from normal and fibrotic human lungs (27). Likewise, inhibitory effects of IFN-gamma on aggrecan and decorin core protein gene expression in cultured human chondrocytes have been reported (10). In addition, IFN-gamma was reported to inhibit experimental renal fibrosis (28). We also examined whether IFN-gamma would interfere with the increased PG expression by fibrotic lung fibroblasts and fibroblasts treated with TGF-beta 1. Our results indicate that IFN-gamma treatment led to a marked decrease in the production of PGs by BLF. Because of the importance of TGF-beta 1 in the regulation of ECM production, the ability of IFN-gamma to decrease the production of PGs by fibroblasts exposed to TGF-beta 1 may have beneficial effects in controlling the excessive PG accumulation in the fibrotic lung. It is possible that IFN-gamma could block the abnormal deposition of PGs in the fibrotic lung by altering TGF-beta 1 gene expression and/or TGF-beta signaling. Consistent with this hypothesis, it was reported that, in the BM-induced model of pulmonary fibrosis, exogenous IFN-gamma downregulates the transcription of the gene for TGF-beta 1 (17), which in turn could modulate the turnover of ECM proteins, including PGs. In contrast, Chen et al. (7) reported that IFN-gamma (-/-) mice exhibited reduced inflammation and fibrosis when treated with BM, suggesting that IFN-gamma may cause inflammation early in the development of BM fibrosis, but its continuous presence either endogenously or administered exogenously may have a net antifibrotic effect. An exciting study by Ziesche et al. (45) demonstrated the potency of IFN-gamma for the treatment of lung fibrosis in humans, revealing an increase in total lung capacity and improved arterial oxygenation that ran parallel with decreases in mRNA levels of TGF-beta and connective tissue growth factor.

In conclusion, our study has demonstrated that rat lung fibroblasts in culture are capable of synthesizing various PGs that are normally expressed in lung tissue. After BM-induced lung injury, these fibroblasts respond with an increased expression of PG; TGF-beta 1 further activates these cells. Because anti-TGF-beta antibody reduced the levels of PGs expressed by these fibroblasts to near- normal levels, our observations indicate an autocrine role for TGF-beta 1. Inhibition of endogenous TGF-beta activity may therefore be of importance in controlling the excessive deposition of ECM components in pulmonary fibrosis. We have also demonstrated that IFN-gamma suppresses the excessive production of PGs by fibrotic lung fibroblasts and fibroblasts exposed to TGF-beta 1. This observation supports a potential therapeutic role for IFN-gamma via modulation of the abnormal deposition of PGs observed during pulmonary fibrosis.


    ACKNOWLEDGEMENTS

We thank Drs. Barbara Tolloczko and Vasanthi Govindaraju for help in immunofluorescence studies. The monoclonal antibodies 12C5, developed by Dr. R. Asher, and C17, developed by Dr. J. R. Sanes, were obtained from the Developmental Studies Hybridoma Bank of the University of Iowa Department of Biological Sciences, Iowa City, IA.


    FOOTNOTES

This work was supported by the J.T. Costello Memorial Research Fund and the Canadian Institutes of Health Research. N. Venkatesan was a recipient of a fellowship from the Canadian Lung Association and the Canadian Institutes of Health Research.

Address for reprint requests and other correspondence: M. S. Ludwig, Meakins-Christie Laboratories, McGill Univ., 3626 Ste. Urbain St., Montreal, QC, Canada H2X 2P2 (E-mail: mara.ludwig{at}mcgill.ca).

The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

June 5, 2002;10.1152/ajplung.00061.2002

Received 15 February 2002; accepted in final form 16 May 2002.


    REFERENCES
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

1.   Al Jamal, R, Roughley PJ, and Ludwig MS. Effect of glycosaminoglycan degradation on lung tissue viscoelasticity. Am J Physiol Lung Cell Mol Physiol 280: L306-L315, 2001[Abstract/Free Full Text].

2.   Bensadoun, ES, Burke AK, Hogg JC, and Roberts CR. Proteoglycan deposition in lung fibrosis. Am J Respir Crit Care Med 154: 1819-1828, 1996[Abstract].

3.   Boehm, U, Klamp T, Groot M, and Howard JC. Cellular responses to interferon-gamma . Annu Rev Immunol 15: 749-795, 1997[ISI][Medline].

4.   Border, WA, Okuda S, Langunio LR, and Ruoslahti E. Transforming growth factor-beta regulates production of proteoglycans by mesangial cells. Kidney Int 37: 689-695, 1990[ISI][Medline].

5.   Border, WA, Okuda S, Langunio LR, Sporn MB, and Ruoslahti E. Suppression of experimental glomerulonephritis by antiserum against transforming growth factor-beta 1. Nature 346: 371-374, 1990[ISI][Medline].

6.   Breen, E, Shull S, Burne S, Absher M, Kelley J, Phan S, and Cutroneo KR. Bleomycin regulation of transforming growth factor-beta mRNA in rat lung fibroblasts. Am J Respir Cell Mol Biol 6: 146-152, 1992[ISI][Medline].

7.   Chen, ES, Greenlee BM, Wills-Karp M, and Moller DR. Attenuation of lung inflammation and fibrosis in interferon-gamma -deficient mice after intratracheal bleomycin. Am J Respir Cell Mol Biol 24: 545-555, 2001[Abstract/Free Full Text].

8.   Crouch, EC. Pathobiology of pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 259: L159-L184, 1990[Abstract/Free Full Text].

9.   Diaz, A, and Jimenez SA. Interferon-gamma regulates collagen and fibronectin gene expression by transcriptional and post-transcriptional mechanisms. Int J Biochem Cell Biol 29: 251-260, 1997[ISI][Medline].

10.   Dodge, GR, Diaz A, Sanz-Rodriguez C, Reginato AM, and Jimenez SA. Effects of interferon-gamma and tumor necrosis factor-alpha on the expression of the genes encoding aggrecan, biglycan, and decorin core proteins in cultured human chondrocytes. Arthritis Rheum 41: 274-283, 1998[ISI][Medline].

11.   Dolhnikoff, M, Morin J, Roughley PJ, and Ludwig MS. Expression of lumican in human lungs. Am J Respir Cell Mol Biol 19: 582-587, 1998[Abstract/Free Full Text].

12.   Ebihara, T, Venkatesan N, Tanaka R, and Ludwig MS. Changes in extracellular matrix and tissue viscoelasticity in bleomycin-induced lung fibrosis. Temporal aspects. Am J Respir Crit Care Med 162: 1569-1576, 2000[Abstract/Free Full Text].

13.   Evans, JN, Kelley J, Low RB, and Adler KB. Increased contractility of isolated lung parenchyma in an animal model of pulmonary fibrosis induced by bleomycin. Am Rev Respir Dis 125: 89-94, 1982[ISI][Medline].

14.   Germain, L, Jean A, Auger FA, and Garrel DR. Human wound healing fibroblasts have greater contractile properties than dermal fibroblasts. J Surg Res 57: 268-273, 1994[ISI][Medline].

15.   Giri, SN, Hyde DM, Braun RK, Gaarde W, Harper JR, and Pierschbacher MD. Antifibrotic effect of decorin in a bleomycin hamster model of lung fibrosis. Biochem Pharmacol 54: 1205-1216, 1997[ISI][Medline].

16.   Giri, SN, Hyde DM, and Hollinger MA. Effect of antibody to transforming growth factor beta on bleomycin induced accumulation of lung collagen in mice. Thorax 48: 959-966, 1993[Abstract].

17.   Gurujeyalakshmi, G, and Giri SN. Molecular mechanisms of antifibrotic effect of interferon gamma in bleomycin-mouse model of lung fibrosis: downregulation of TGF-beta and procollagen I and III gene expression. Exp Lung Res 21: 791-808, 1995[ISI][Medline].

18.   Hakkinen, L, Westermarck J, Kahari VM, and Larjava H. Human granulation-tissue fibroblasts show enhanced proteoglycan gene expression and altered response to TGF-beta 1. J Dent Res 75: 1767-1778, 1996[Abstract].

19.   Hoyt, DG, and Lazo JS. Alterations in pulmonary mRNA encoding procollagens, fibronectin and transforming growth factor-beta precede bleomycin-induced pulmonary fibrosis in mice. J Pharmacol Exp Ther 246: 765-771, 1988[Abstract].

20.   Iozzo, RV. Matrix proteoglycans: from molecular design to cellular function. Annu Rev Biochem 67: 609-652, 1998[ISI][Medline].

21.   Iozzo, RV, and Murdoch AD. Proteoglycans of the extracellular environment: clues from the gene and protein side offer novel perspectives in molecular diversity and function. FASEB J 10: 598-614, 1996[Abstract/Free Full Text].

22.   Kahari, VM, Larjava H, and Uitto J. Differential regulation of extracellular matrix proteoglycan (PG) gene expression. Transforming growth factor-beta 1 upregulates biglycan (PG), and versican (large fibroblast PG) but down-regulates decorin (PGII) mRNA levels in human fibroblasts in culture. J Biol Chem 266: 10608-10615, 1991[Abstract/Free Full Text].

23.   Khalil, N, and Greenberg AH. The role of TGF-beta in pulmonary fibrosis. Ciba Found Symp 157: 194-207, 1991[ISI][Medline].

24.   Kuhn, C, and McDonald JA. The roles of the myofibroblast in idiopathic pulmonary fibrosis. Am J Pathol 138: 1257-1265, 1991[Abstract].

25.   Logan, A, Green J, Hunter A, Jackson R, and Berry M. Inhibition of glial scarring in the injured rat brain by a recombinant human monoclonal antibody to transforming growth factor-beta 2. Eur J Neurosci 11: 2367-2374, 1999[ISI][Medline].

26.   Mitchell, J, Woodcock-Mitchell J, Reynolds S, Low R, Leslie K, Adler K, Gabbiani G, and Skalli O. alpha -Smooth muscle actin in parenchymal cells of bleomycin-injured rat lung. Lab Invest 60: 643-650, 1989[ISI][Medline].

27.   Narayanan, AS, Whithey J, Souza A, and Raghu G. Effects of gamma -interferon on collagen synthesis by normal and fibrotic human lung fibroblasts. Chest 101: 1326-1331, 1992[Abstract].

28.   Oldroyd, SD, Thomas GL, Gabbiani G, and El Nahas AM. Interferon-gamma inhibits experimental renal fibrosis. Kidney Int 56: 2116-2127, 1999[ISI][Medline].

29.   Otsuka, K, Murota S, and Mori Y. Stimulatory effect of bleomycin on the synthesis of acid glycosaminoglycans in cultured fibroblasts derived from a rat carrageenin granuloma. Biochim Biophys Acta 444: 359-368, 1976[ISI][Medline].

30.   Phan, SH, Varani J, and Smith D. Rat lung collagen metabolism in bleomycin-induced pulmonary fibrosis. J Clin Invest 76: 241-247, 1985[ISI][Medline].

31.   Raghu, G, Masta S, Meyers D, and Narayanan AS. Collagen synthesis by normal and fibrotic human lung fibroblasts and the effect of transforming growth factor-beta . Am Rev Respir Dis 140: 95-100, 1989[ISI][Medline].

32.   Regan, MC, Kiek SJ, Wasserkrug HL, and Barbul A. The wound environment as a regulator of fibroblast phenotype. J Surg Res 50: 442-448, 1991[ISI][Medline].

33.   Roberts, CR, Wight TN, and Hascall VC. Proteoglycans. In: The Lung: Scientific Foundations (2nd. ed.), edited by Crystal RG, West JB, Barnes PJ, and Weibel ER.. Philadelphia, PA: Lippincott-Raven, 1997, p. 757-767.

34.   Roughley, PJ, White RJ, Magny MC, Liu J, Pearce RH, and Mort JS. Non-proteoglycan forms of biglycan increase with age in human articular cartilage. Biochem J 295: 421-426, 1993[ISI][Medline].

35.   Ruoslahti, E, and Yamaguchi Y. Proteoglycans as modulators of growth factor activities. Cell 64: 867-869, 1991[ISI][Medline].

36.   Schonherr, E, Jarvelainen HT, Sandell LJ, and Wight TN. Effects of platelet-derived growth factor and transforming growth factor-beta 1 on the synthesis of a large versican-like chondroitin sulfate proteoglycan by arterial smooth muscle cells. J Biol Chem 266: 17640-17647, 1991[Abstract/Free Full Text].

37.   Sime, PJ, and O'Reilly KMA Fibrosis of the lung and other tissues: new concepts in pathogenesis and treatment. Clin Immunol Immunopathol 99: 308-319, 2001.

38.   Tiedemann, K, Malmstrom A, and Westergren-Thorsson G. Cytokine regulation of proteoglycan production in fibroblasts: separate and synergistic effects. Matrix Biol 15: 469-478, 1996[ISI].

39.   Tipton, DA, and Dabbous MK. Autocrine transforming growth factor beta  stimulation of extracellular matrix production by fibroblasts from fibrotic human gingiva. J Periodontol 69: 609-619, 1998[ISI][Medline].

40.   Venkatesan, N, Ebihara T, Roughley PJ, and Ludwig MS. Alterations in large and small proteoglycans in bleomycin-induced pulmonary fibrosis in rats. Am J Respir Crit Care Med 161: 2066-2073, 2000[Abstract/Free Full Text].

41.   Wang, Q, Wang Y, Hyde DM, Gotwals PJ, Koteliansky VE, Ryan ST, and Giri SN. Reduction of bleomycin induced lung fibrosis by transforming growth factor beta soluble receptors in hamsters. Thorax 54: 805-812, 1999[Abstract/Free Full Text].

42.   Wegrowski, Y, Gillery P, Serpier H, Georges N, Combemale P, Kalis B, and Maquart FX. Alteration of matrix macromolecule synthesis by fibroblasts from a patient with pachydermoperiostosis. J Invest Dermatol 106: 70-74, 1996[Abstract].

43.   Westergren-Thorsson, G, Hernnas J, Sarnstrand B, Oldberg A, Heinegard D, and Malmstrom A. Altered expression of small proteoglycans, collagen and transforming growth factor-beta 1 in developing bleomycin-induced pulmonary fibrosis in rats. J Clin Invest 92: 632-637, 1993[ISI][Medline].

44.   Zhang, H, Gharaee-Kermani M, Zhang K, Karmiol S, and Phan SM. Lung fibroblast alpha -smooth muscle actin expression and contractile phenotype in bleomycin-induced pulmonary fibrosis. Am J Pathol 148: 527-537, 1996[Abstract].

45.   Ziesche, R, Hofbauer E, Wittmann K, Petkov V, and Block LH. A preliminary study of long-term treatment with interferon gamma-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis. N Engl J Med 341: 1264-1269, 1999[Abstract/Free Full Text].


Am J Physiol Lung Cell Mol Physiol 283(4):L806-L814
1040-0605/02 $5.00 Copyright © 2002 the American Physiological Society